Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are you referring to cyrxw, or are you implying exercising our warrants at $3? If you buy the cyrxw, those warrants are for stock at $3.57, expiring in 2020 I believe. The time value/premium is small today at around .40/share, hence most of the price is based on the common price, so if we 'settle down' to say $4 a share, or 20%, I'm assuming the tradeable warrants will fall significantly more. The spread is terrible with those things and hard to pick any up without hitting the ask. With commmon, at least you don't hit any time constraints, as you never know when they pull another 'we need to prove we can raise money when needed' stunt. We were at $2/share just a couple months ago. If they raise money again...you can bet it'll be at a STEEP discount to common.
Maybe pessimistic, but its been a long road to get near $5 again.
Well, it literally came to the door in the last 30 minutes, so don't sweat, they're coming.
I remember someone mentioning the $4.50 for 10 day warrant conversion a while back, that's why I'm bringing that up again, its a bit curious that they were SOOO prepared to send these docs out just a day or two after the price closed for the 10th consecutive day at $4.50.
Do they really need more money already, or are they just trying to clean up their cap table? Or was this done for another reason by another large shareholder?
So do you think this recent strength is strictly to clean out the $3 warrants? Just received a fedex with my remaining warrants, which $4.50 for 10 consecutive days triggers the expiration date to be moved from 2019 to july 27th 2017.
I'm really wondering if the recent support will now dry up and the price will correct or not. Does it pay to buy and 'create' more shares by the warrants, or do we wait to see if the support goes away and we settle down around that $3 mark.
Problem with the warrants is its a pain to get them liquid once exercised...
Yeah, saw that but just now noticed 'individually calculated refrigerants to maintain in spec temperatures for up to 120 hours'. So 5 days, with what appears to be little tracking/visibility capabilities(or it would say that in bold type). Appears they are well behind Cryoport, probably for the simple fact that its not their niche...yet, or maybe they just didn't see the train coming until it was too late.
Oh and I wonder which one of us posted that comment below that article???
So the author is president of ICS, a division of AmericourseBergen(?), it would appear this is almost an advertisement for whatever solution they provide as they are a fortune 500 company providing logistics for pharma.
Can't find anything on their cryogenic logistics capabilities but having the big names on board with Cryoport has to say something about the lack of their expertise...
Maybe they need to add some expertise to their portfolio...like buying Cryoport, let the bidding war begin
Nice find Mike,
And to add to the 'who makes the containers', is the whole logistics visibility is likely the CryoPortal. Just hope the bottom line benefits from the backend services that are provided.
I really like the last line of the paragraph “The process today is not 2017 technology, it’s 2010 technology ... that’s fine for dealing with academic centres that handle five to 10 patients a year, but we have to figure out a process for tens of thousands.”
Better days ahead!
No idea, very quiet, buddy that studied their trials swears they have something special, guess we'll find out eventually. Hate taking tips from friends cause 9 of 10 times theyre full of it...
Im in at 2.83, hoping we get a pre conference bump!
Wow, Shelton is now making 550k salary...wonder how they justified that number, being about 5% of total revenues...
Well even though Im down 30% on opko, I believe 6ish is a very decent entry point. This company has so much potential the downside risk is minimal. Midsize biotech with good revenues.
Buy near lows on NO news, not at highs after news.
Are you implying Opko may turn around sooner than later?
So whats up with the tradeable warrants? Sign of things to come, or is someone getting ahead of themselves? Trading at huge premium right now...
You know, for just having a substantial money raise at $2, the stock is looking really strong! This has to be 'smart' money buying, hopefully a positive sign of things to come...
Talon you said 'The slow down in released P2 trial data is in my estimation the result of partnership negotiations.'
If in negotiations for partnership, and the data is GOOD, why not make it public...that would ensure the best deal and most competition between potential partners.
Looks to me like MVTG is going to roll over and cook whoever has been buying on the way up. No volume...you've been pumping this on many boards, in too deep?
Nice analysis, thanks for sharing!
Positive report from zacks today, posted on yahoo finance if interested. It says cash burn has been flat last number of quarters and current cash on hand should be sufficient for 2.5 years at the burn rate. They also pointed out they have done very well cutting operating(?) expenses while growing revs. Gross margins up nice again, from 42 just last quarter to 46 this quarter.
They must have indicated on the conference call the last capital raise was to assure the customers about to commercialize they have enough resources to support them. We can hope its the last...we may be close (within a year?) of finding out if their business model is very profitable or not.
Too bad I didnt wait until now to invest, seems like now it's gettin real, with decent numbers and 'real' opportunities in the pipeline.
Might try for a few more tradeable warrants in the .80 range...
I know its very frustrating, I've participated in a couple cyrx money raises through emergent. The only thing that keeps me invested here, is the potential that we all know is here.
They have had SOME revenue growth, tons of potential but feels like the target market is just flailing along with little advance.
They have a wonderful product with needed/mandated high tech capabilities but the longer this market takes to mature the more competition we will face. Possibly more new solutions other than cryogenic shipping, will they have other means of processing the cells onsite eliminating the need for cryogenic shipping, small chance in the near future but at this rate that might be the new solution.
I'm still hopeful mostly because I know more about Cryoport and its future is likely bright, but when? Obviously our return gets cut every time they raise capital but there is still this calm about my investment being more secure than other companies I know little about. I'm a long term holder and not a trader.
Wonder if we'll have a pre-earnings bump? Any guesses on revs? I'll go conservative this time and say 2.2m...
thanks for the reply, it does appear more confirmation is in need.
Although one needs to be anticipatory when investing. I like the MFI moving up aggressively here, accum/dist improving, macd close to crossing 0. Looks like good base is setting, now I need to look at business and see if anything going on. I honestly don't know what this company does:)
https://www.barchart.com/stocks/quotes/seac/technical-chart#/technical-chart?plot=BAR&volume=total&data=WO&density=X&pricesOn=1&asPctChange=0&logscale=0&indicators=TREND;ACCUM;SMACD(12,26,9);MFI(14,100)&sym=SEAC&grid=1&height=500&studyheight=100
Hey Stockman, what do you think of this now? Chart looks better, possible move up soon?
THERE IT IS!!! Lol
Anyone watching this? They have lots of cash, tiny float, but no idea what their business plan is...
Based on lack of news im not getting too excited about earnings. Anyone seen their hockey stick? They must have lost it...
It would appear this last money raise has something to do with it. Even though it was announced to be closed, I wonder if Needham and Cowen(?) are supporting the stock price...
Looking at the latest financials, they only had 6m in the bank on Dec 31st. They need money NOW. Not sure what this little 1m share offer is all about, but they are burning $50m a year or more, with big debt due this year. So expect some massive dilution or a fire sale of the company.
Anyone closer to the situation please let me know if I'm way off base here...
Reading through the proxy materials the proposed preffered shares are 'open check'. Terms haven't been decided, these are not 'common' shares, we cannot speak to how dilutive they would be, or how expensive they would be, and they always have preference to common in a liquidation event. Who knows what they'll consist of, they could sell the preferred at $100 and have a conversion right of 100 shares if they wanted to. They could earn interest at 10% until conversion...we have no idea what damage they can cause. At least raising money by selling common is transparent and easy for everyone to account for...
So these 2 small 'insider buys' reported must be exercised options? Both the same size, indicates both at 2.08? Not that it means much, would be nice to see more insider buying on open market...lack of open market buying shows little insider confidence in stock price.
I was poking fun of Cryoport management....
Why would anyone put millions of dollars into developing what Cryoport does....aint no money it :)
I've been looking for information as to how Osiris' product works but the press release is the only thing I can find. Their website doesn't even list it as an available product/service yet. The press release states this product can preserve 'living cells inside tissue'.
I cannot imagine this technology will be any threat in the near term, as it likely would take a long time to certify the efficacy of shipping cells with no change in their biological makeup with this new wondrous product. They 'developed it' but it doesn't appear to be validated by any independent body, sure they have an article in 'nature magazine', but that doesn't mean it works as advertised.
What would it take for the Kites and Novartis of the world to abandon cryopreservation when it simply works, to go with a new wizbang product suddenly announced, to support their critical business? Just like anything else in the medical field, it has to be independently tested, proven and certified, and that takes a long time.
With Cryopreservation, you know the cells are alive and well if they stay at Cryo temps during transport, they are the same when they arrive, Cryoport can certify that. Too many questions with Osiris product.
That wasn't predictable...Needham put out a buy rating...
https://www.streetinsider.com/Analyst+Comments/Needham+%26+Company+Starts+CryoPort+(CYRX)+at+Buy/12734304.html
Dont feel bad I added at 2.07...
Excellent fine laser! THAT would be a very logical explanation why this 'quick and dirty' money raise happened. Not only is Kite filing for commercialization soon, now Novartis is racing to be the first. Even if an FDA decision is 3 months away, they need to prep for commercialization now. I would imagine a 'shipping' agreement will be in place long before an FDA decision.
I'm getting sucked in a again...
However frustrating today was...we traded more volume than probably the last year combined, can't imagine much downside from here.
Even with the additional 5.5m shares the market cap is what 30% less than yesterday? Im trying to look at this without emotion to figure out if adding more to my already overweight holdings is the right thing to do. We are after all closer to a nice supportive event than we have ever been.
Hoping this money raise was due to a big announcement coming...of course 'hope' seldom works when investing.
They better have a darn good reason for raising more money. Better be at follow-up announcement soon or look out below.
Who are you? One post on investors hub?
Dr M has a modest salary of around 300k, VERY modest. Where his real compensation comes in is with stock options vesting over a number of years...nice way to incentivise good performance. Please do some reading and quit throwing inaccurate acusations around.
Well I like the strength today after a not so stellar quarterly report. More 'waiting' for a really big announcement is imo warranted. They did allude to some pretty good developments coming.
The biggest worry I have is the gross margins that don't appear to have moved much, it feels like they lose the same percent of money no matter how much revenue they have. If revenue grows by 53%, and gross margins don't budge very much, how long until they actually make cash flow positive??? If anyone is more versed in this topic please chime in.
I know 'economies of scale' kick in sometime, but how long will we wait before they do not need to raise more capital? Is a FDA approval/phase III finish line going to get us where we need to be?
So much potential, so little time...
Yep, another ho hum quarter. They were however very confident one or possibly three commercializations this year. Im wondering if margins will improve on insurance reimbursed treatments...in other words, if theyll be able to charge more for the finished product. During all trials i assume the trial sponsors pay the bulk of the cost.